Ischemic stroke remains the second leading cause of death globally and the single largest source of long-term adult disability. Even when thrombolysis or mechanical thrombectomy restores blood flow, a sizable minority of patients are left with fixed neurologic deficits. The acute window closes, inflammation lingers, and endogenous repair mechanisms struggle to keep pace. That residual injury is precisely what MSC therapy for ischemic stroke is being designed to modulate — not by replacing neurons directly, but by reshaping the post-stroke microenvironment so the brain can rebuild around the infarct.
This week, a new phase 1 trial published in Cell Reports Medicine gives clinicians the clearest look yet at intravenous umbilical cord-derived mesenchymal stem cells (UC-MSCs) in subacute stroke. The trial, named MERIT, moves the conversation from small feasibility studies toward a more structured safety and dosing signal.
MERIT: Intravenous UC-MSCs in Subacute Ischemic Stroke
Cui and colleagues conducted an open-label, single-arm phase 1 study evaluating a single intravenous infusion of allogeneic UC-MSCs in 18 patients with subacute ischemic stroke. Eligible participants had NIH Stroke Scale (NIHSS) scores between 6 and 20, a median baseline of 9, and were treated after the hyperacute window had passed. Three dose levels were tested: 50 million, 100 million, and 200 million cells, with six patients per cohort.
The primary endpoint was safety and tolerability over 24 weeks. Possible treatment-related adverse events were mostly mild: dizziness, nausea, sweating, fatigue, and one seizure episode. No serious adverse events were attributed to the cells, and no dose-limiting toxicity emerged.
Secondary efficacy signals were preliminary but encouraging:
- Fourteen of eighteen patients showed NIHSS reductions of 1–5 points during follow-up.
- The absence of immunological surprises suggests allogeneic UC-MSCs were well-tolerated even with systemic intravenous delivery.
- The trial was registered on ClinicalTrials.gov under NCT05697718.
It is important not to oversell phase 1 data. There was no control arm, no blinding, and the sample size was modest. Yet the clean safety profile across a ten-fold dose escalation range provides a foundation for a powered phase 2 trial. For physicians, the key takeaway is that intravenous UC-MSC delivery appears feasible in the subacute period without adding prohibitive risk.
Why the Subacute Window Matters
Most stroke interventions focus on the first hours. After that, care shifts to rehabilitation and secondary prevention. The subacute phase — roughly days to a few weeks post-stroke — is increasingly recognized as a therapeutic window in its own right. Inflammation is still active, microglia and macrophages patrol the injured tissue, and the blood-brain barrier remains permissive enough to allow circulating cells and paracrine signals to reach the injury site.
MSCs appear to act through several coordinated mechanisms during this window. They dampen pro-inflammatory cytokine release, polarize macrophages toward an anti-inflammatory phenotype, promote angiogenesis, and secrete extracellular vesicles that support neuronal and vascular remodeling. A recent review in Experimental Neurology argues that this multi-modal paracrine activity is the principal mechanism by which MSCs improve long-term functional recovery after ischemic stroke, rather than direct neuronal replacement.
MRI Biomarkers: Objectifying Recovery
One persistent challenge in cell therapy trials is proving that a treatment changes brain structure or connectivity, not just bedside scores. A systematic review in the Journal of Clinical Neuroscience pooled eleven clinical trials totaling 513 stroke patients treated with MSCs, mononuclear cells, or neural stem cells. The authors found that MSC trials showed the most consistent associations between motor improvement and objective MRI changes.
Specifically, diffusion tensor imaging showed preserved or increased fractional anisotropy in the corticospinal tract, and task-based fMRI revealed greater BOLD activity in motor regions BA4 and BA6. These imaging markers do not replace clinical endpoints, but they give trialists a measurable readout of tissue-level remodeling that is hard to fake or attribute to placebo.
Extracellular Vesicles: The Next Layer of the Story
Not all of MSCs’ benefits require intact cells. Another June 2026 review in Stem Cell Reviews and Reports describes how MSC-derived extracellular vesicles can transfer bioenergetically active mitochondria, mitochondrial DNA, and transcriptional proteins to injured recipient cells. In neurological injury models, EV-mediated mitochondrial rescue has been linked to restored membrane potential, lower oxidative stress, and reduced hyper-inflammation.
For stroke, this is a plausible adjunctive mechanism. If intravenous MSCs enrich the peri-infarct environment with EVs carrying functional mitochondria and anti-inflammatory cargo, they may support both neuronal survival and glial reprogramming. Standardization remains a barrier — the field still needs MISEV-compliant isolation protocols and larger clinical trials — but the mechanistic rationale is strengthening.
Clinical Translation: What We Still Need
MERIT is a welcome step, but it leaves several questions on the table. A single-arm design cannot separate drug effect from natural recovery, especially when patients were enrolled in the subacute phase. The study was also industry-supported, with one author as CEO and another an employee of the cell-product manufacturer. That relationship does not invalidate the data, but it underscores why independent replication in a randomized, double-blind phase 2 trial matters.
Here is what clinicians should watch for in the next trial generation:
- Randomized placebo control with NIHSS and modified Rankin Scale co-primary endpoints.
- Longer follow-up, ideally 12 months, because functional gains after stroke can evolve over weeks to months.
- Pre-specified MRI biomarkers, ideally DTI and rs-fMRI, to correlate structural changes with clinical outcomes.
- Clear characterization of the cell product: passage number, potency assays, donor criteria, and release standards.
The Bottom Line for Referring Physicians
The MERIT phase 1 trial supports what earlier feasibility studies hinted: intravenous UC-MSC therapy in subacute ischemic stroke is tolerable and shows early functional signals. It does not yet change standard of care. It does, however, strengthen the rationale for referring appropriate chronic or subacute stroke patients into well-regulated, ethically run cell therapy programs while the Phase 2 evidence base matures.
At Cell La Vie, we follow these data closely because treatment decisions should be anchored in published mechanisms and transparent trial outcomes, not marketing claims.
References
- Cui L, Xiao M, Zhang Q, et al. Intravenous human umbilical cord-derived mesenchymal stem cell transplantation for ischemic stroke (MERIT): A phase 1 trial. Cell Rep Med. 2026 Jun 16;7(6):102836. doi: 10.1016/j.xcrm.2026.102836. ClinicalTrials.gov: NCT05697718.
- Li S, Huang H, Deng W, et al. Mesenchymal stem cells therapy for ischaemic stroke: Mechanism and progress. Exp Neurol. 2026 Aug;402:115795. doi: 10.1016/j.expneurol.2026.115795.
- Elhaie M, Zamanian M, Golkar Z, et al. MRI biomarkers of post-stroke stem cell implantation and motor recovery: systematic review of clinical trials. J Clin Neurosci. 2026 Aug;150:112036. doi: 10.1016/j.jocn.2026.112036.
- Ma T, He Y, Yang J, et al. Mesenchymal Stromal Cell-Derived Extracellular Vesicles Mediate Mitochondrial Delivery in Injury: Mechanistic Insights, Evidentiary Tiers, and Translational Challenges. Stem Cell Rev Rep. 2026 Jun 17. doi: 10.1007/s12015-026-11170-0.